 |
|
JAMA-EXPRESS
Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery DiseaseThe STRADIVARIUS Randomized Controlled Trial
Steven E. Nissen, MD;
Stephen J. Nicholls, MBBS, PhD;
Kathy Wolski, MPH;
Josep Rodés-Cabau, MD;
Christopher P. Cannon, MD;
John E. Deanfield, MD;
Jean-Pierre Després, PhD;
John J. P. Kastelein, MD, PhD;
Steven R. Steinhubl, MD;
Samir Kapadia, MD;
Muhammad Yasin, MD;
Witold Ruzyllo, MD;
Christophe Gaudin, MD;
Bernard Job, MD;
Bo Hu, PhD;
Deepak L. Bhatt, MD;
A. Michael Lincoff, MD;
E. Murat Tuzcu, MD; for the STRADIVARIUS Investigators
JAMA. 2008;299(13):1547-1560. Published online April 1, 2008 (doi:10.1001/jama.299.13.1547).
Context Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease.
Objective To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor antagonist rimonabant reduces progression of coronary disease in patients with abdominal obesity and the metabolic syndrome.
Design, Setting, and Patients Randomized, double-blinded, placebo-controlled, 2-group, parallel-group trial (enrollment December 2004-December 2005) comparing rimonabant with placebo in 839 patients at 112 centers in North America, Europe, and Australia.
Interventions Patients received dietary counseling, were randomized to receive rimonabant (20 mg daily) or matching placebo, and underwent coronary intravascular ultrasonography at baseline (n = 839) and study completion (n = 676).
Main Outcome Measures The primary efficacy parameter was change in percent atheroma volume (PAV); the secondary efficacy parameter was change in normalized total atheroma volume (TAV).
Results In the rimonabant vs placebo groups, PAV (95% confidence interval [CI]) increased 0.25% (–0.04% to 0.54%) vs 0.51% (0.22% to 0.80%) (P = .22), respectively, and TAV decreased 2.2 mm3 (–4.09 to –0.24) vs an increase of 0.88 mm3 (–1.03 to 2.79) (P = .03). In the rimonabant vs placebo groups, imputing results based on baseline characteristics for patients not completing the trial, PAV increased 0.25% (–0.04% to 0.55%) vs 0.57% (0.29% to 0.84%) (P = .13), and TAV decreased 1.95 mm3 (–3.8 to –0.10) vs an increase of 1.19 mm3 (–0.73 to 3.12) (P = .02). Rimonabant-treated patients had a larger reduction in body weight (4.3 kg [–5.1 to –3.5] vs 0.5 kg [–1.3 to 0.3]) and greater decrease in waist circumference (4.5 cm [–5.4 to –3.7] vs 1.0 cm [–1.9 to –0.2]) (P < .001 for both comparisons). In the rimonabant vs placebo groups, high-density lipoprotein cholesterol levels increased 5.8 mg/dL (4.9 to 6.8) (22.4%) vs 1.8 mg/dL (0.9 to 2.7) (6.9%) (P < .001), and median triglyceride levels decreased 24.8 mg/dL (–35.4 to –17.3) (20.5%) vs 8.9 mg/dL (–14.2 to –1.8) (6.2%) (P < .001). Rimonabant-treated patients had greater decreases in high-sensitivity C-reactive protein (1.3 mg/dL [–1.7 to –1.2] [50.3%] vs 0.9 mg/dL [–1.4 to –0.5] [30.9%]) and less increase in glycated hemoglobin levels (0.11% [0.02% to 0.20%] vs 0.40% [0.31% to 0.49%]) (P < .001 for both comparisons). Psychiatric adverse effects were more common in the rimonabant group (43.4% vs 28.4%, P < .001).
Conclusions After 18 months of treatment, the study failed to show an effect for rimonabant on disease progression for the primary end point (PAV) but showed a favorable effect on the secondary end point (TAV). Determining whether rimonabant is useful in management of coronary disease will require additional imaging and outcomes trials, which are currently under way.
Trial Registration clinicaltrials.gov Identifier: NCT00124332
Author Affiliations: Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine (Drs Nissen, Nicholls, Kapadia, Bhatt, Lincoff, and Tuzcu and Ms Wolski) and Department of Quantitative Health Sciences, Cleveland Clinic (Dr Hu), Cleveland, Ohio; Laval Hospital and Quebec Heart Institute, Quebec City, Canada (Drs Rodés-Cabau and Després); TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Dr Cannon); University College, London, England (Dr Deanfield); Academic Medical Center, Amsterdam, the Netherlands (Dr Kastelein); University of Kentucky, Lexington (Dr Steinhubl); Southwest Cardiology, Oklahoma City, Oklahoma (Dr Yasin); Instytut Kardiologii I Klinika Warsaw, Warsaw, Poland (Dr Ruzyllo); and sanofi-aventis, Paris, France (Drs Gaudin and Job).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Rimonabant and Progression of Atherosclerosis in Obese Persons
José Miguel Dora and Rafael Selbach Scheffel
JAMA. 2008;300(3):280.
EXTRACT
| FULL TEXT
Rimonabant and Progression of Atherosclerosis in Obese Persons—Reply
Steven E. Nissen, Stephen J. Nicholls, and Kathy Wolski
JAMA. 2008;300(3):280-281.
EXTRACT
| FULL TEXT
RELATED ARTICLE
The Hope and Fear of Rimonabant
John S. Rumsfeld and Brahmajee K. Nallamothu
JAMA. 2008;299(13):1601-1602.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia
Florentin et al.
J CARDIOVASC PHARMACOL THER 2009;14:274-282.
ABSTRACT
CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages
Han et al.
Cardiovasc Res 2009;84:378-386.
ABSTRACT
| FULL TEXT
Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
Butler and Korbonits
Eur J Endocrinol 2009;161:655-662.
ABSTRACT
| FULL TEXT
Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?
Nilsson
Diabetes Care 2009;32:S290-S293.
FULL TEXT
Rimonabant may induce atrial fibrillation
Cocco and Chu
BMJ 2009;338:b1061-b1061.
FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2009;53:1326-1337.
FULL TEXT
Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease
Mathieu et al.
Hypertension 2009;53:577-584.
FULL TEXT
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
Chhatriwalla et al.
J Am Coll Cardiol 2009;53:1110-1115.
ABSTRACT
| FULL TEXT
Atheroma volume by intravascular ultrasound as a surrogate for clinical end points.
Tobis and Perlowski
J Am Coll Cardiol 2009;53:1116-1118.
FULL TEXT
ADAGIO-Lipids Gives Promises but Faces the Setbacks
Taskinen
Arterioscler. Thromb. Vasc. Bio. 2009;29:339-340.
FULL TEXT
Effect of Rimonabant on the High-Triglyceride/ Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial
Despres et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:416-423.
ABSTRACT
| FULL TEXT
Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich et al.
Ther Adv Cardiovasc Dis 2009;3:75-90.
ABSTRACT
Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages
Sugamura et al.
Circulation 2009;119:28-36.
ABSTRACT
| FULL TEXT
Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns?
Pacher
Arterioscler. Thromb. Vasc. Bio. 2009;29:7-9.
FULL TEXT
Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor-Deficient Mice
Dol-Gleizes et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:12-18.
ABSTRACT
| FULL TEXT
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT
American College of Endocrinology Pre-Diabetes Consensus Conference: Part Two
Bloomgarden
Diabetes Care 2008;31:2222-2229.
FULL TEXT
Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety
Bray
J. Clin. Endocrinol. Metab. 2008;93:s81-s88.
ABSTRACT
| FULL TEXT
Modulation of the Endocannabinoid System in Cardiovascular Disease: Therapeutic Potential and Limitations
Pacher et al.
Hypertension 2008;52:601-607.
FULL TEXT
A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT
| FULL TEXT
Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism
Andrikopoulos and Tzeis
ANGIOLOGY 2008;59:44S-48S.
ABSTRACT
Rimonabant and Progression of Atherosclerosis in Obese Persons
Dora and Scheffel
JAMA 2008;300:280-280.
FULL TEXT
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS
Kintscher
Eur Heart J 2008;29:1709-1710.
FULL TEXT
The Hope and Fear of Rimonabant
Rumsfeld and Nallamothu
JAMA 2008;299:1601-1602.
FULL TEXT
A Weight-Loss Drug for Atherosclerosis?
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT
|
